Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Vascular access site bleeding is a significant complication in percutaneous coronary interventions.
• Abciximab, an antiplatelet agent, has been associated with increased bleeding risk.

Purpose of the Study:

• To quantify the reduction in vascular access site bleeding complications across the EPIC, EPILOG, and EPISTENT trials.
• To assess the impact of abciximab on bleeding complications over time and with evolving management strategies.

Main Methods:

• Analysis of pooled data from three large-scale clinical trials: EPIC, EPILOG, and EPISTENT.
• Comparison of vascular access site bleeding rates (major and minor) between patients receiving abciximab and those receiving placebo (or heparin alone).
• Statistical analysis to determine the significance of observed bleeding rate changes and the effect of abciximab.

Main Results:

• A progressive and significant decrease in combined major and minor vascular access site bleeding was observed in both non-abciximab and abciximab groups across the trials (P < 0.001).
• While abciximab was associated with more major bleeds in the EPIC trial (OR 3.2), this difference was not significant in EPILOG or EPISTENT.
• The incidence of bleeding complications in abciximab patients decreased substantially from EPIC (20%) to EPILOG (5.8%) and EPISTENT (2.2%).

Conclusions:

• Modified dosing strategies for abciximab and heparin, coupled with enhanced vascular access site management, have significantly reduced bleeding risks.
• The excess vascular access site bleeding historically associated with abciximab has been effectively mitigated through these advancements.
• These findings support the continued use of abciximab in conjunction with optimized protocols for coronary interventions.